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ROS/TRPA1/CGRP signaling mediates
cortical spreading depression
Liwen Jiang1,2,3, Dongqing Ma1,2, Blair D. Grubb3 and Minyan Wang1,2*
Abstract
Objectives: The transient receptor potential ankyrin A 1 (TRPA1) channel and calcitonin gene-related peptide
(CGRP) are targets for migraine prophylaxis. This study aimed to understand their mechanisms in migraine
by investigating the role of TRPA1 in cortical spreading depression (CSD) in vivo and exploring how reactive
oxygen species (ROS)/TRPA1/CGRP interplay in regulating cortical susceptibility to CSD.
Methods: Immunohistochemistry was used for detecting TRPA1 expression. CSD was induced by K+ on the
cerebral cortex, monitored using electrophysiology in rats, and intrinsic optical imaging in mouse brain slices,
respectively. Drugs were perfused into contralateral ventricle of rats. Lipid peroxidation (malondialdehyde, MDA)
analysis was used for indicating ROS level.
Results: TRPA1 was expressed in cortical neurons and astrocytes of rats and mice. TRPA1 deactivation by an anti-TRPA1
antibody reduced cortical susceptibility to CSD in rats and decreased ipsilateral MDA level induced by CSD. In mouse
brain slices, H2O2 facilitated submaximal CSD induction, which disappeared by the antioxidant, tempol and the TRPA1
antagonist, A-967079; Consistently, TRPA1 activation reversed prolonged CSD latency and reduced magnitude by the
antioxidant. Further, blockade of CGRP prolonged CSD latency, which was reversed by H2O2 and the TRPA1 agonist,
allyl-isothiocyanate, respectively.
Conclusions: ROS/TRPA1/CGRP signaling plays a critical role in regulating cortical susceptibility to CSD. Inhibition ROS
and deactivation of TRPA1 channels may have therapeutic benefits in preventing stress-triggered migraine via CGRP.
Keywords: Migraine, Cortical spreading depression, Transient receptor potential ankyrin a 1, Reactive oxygen species,
Calcitonin gene-related peptide
Article highlights
 Deactivation of TRPA1 reduces the likelihood for
CSD occurrence in rats, which coincides with lower
level of lipid peroxidation induced by CSD.
 ROS/TRPA1/CGRP signaling plays a critical role in
regulating cortical susceptibility to CSD, which is of
central mechanism.
 Reduction of ROS production and blockade of
TRPA1 may have therapeutic benefits in preventing
stress-triggered migraine.
Introduction
Migraine is a complex disabling neurovascular disorder,
which has unmet therapeutic need due to its compli-
cated mechanism that is not yet fully understood.
Cortical spreading depression (CSD) is a key patho-
physiological basis of migraine aura [1–3]. The import-
ance of CSD in migraine pathogenesis is supported by
that inhibition of calcitonin gene-related peptide (CGRP)
and its receptor not only prevents chronic and episodic
migraine [1, 4], but also suppresses cortical susceptibility
to CSD [5, 6]. One common factor for almost all mi-
graine triggers is reactive oxygen species (ROS) [7]. In-
creased ROS is associated with migraine [8, 9] but
also with CSD in the trigeminal nociceptive system
[10]. This is supported by that the antioxidant, tem-
pol, strongly reduces the CSD occurrence in vivo
[11]; while the lowered-CSD threshold level is considered
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as stress-induced susceptibility to migraine [12]. Given
that CSD activates trigeminovascular neurons and menin-
geal nociceptors [13, 14], molecules in the oxidative stress
pathway that can modulate CSD are likely to be important
targets in stress-related migraine.
One such emerging drug target for migraine preven-
tion involves the transient receptor potential ankyrin
type 1 (TRPA1). TRPA1 is sensitive to oxidative stress
and is a type of nonselective transmembrane cation
channel with 14–18 ankyrin repeats in its N-terminus
depending on species. This channel is widely expressed
in rodent cerebral cortex [15, 16], hippocampus [16–18]
and trigeminal nociceptive system [19], yet TRPA1 dis-
tribution in cortical neurons or glias is not known.
TRPA1 deactivation has been recently reported to coun-
teract nitroglycerin-induced hyperalgesia [20]; whilst the
channel activation mediates allodynia induced by gly-
ceryl trinitrate in mice [21]. Coincidently, we recently
show that TRPA1 plays a key role in mediating CSD in
the mouse brain slice [5], suggesting TRPA1 as a drug
target for preventing migraine aura. However, whether
deactivation of TRPA1 reduces cortical susceptibility to
CSD in vivo where vascular components and immune
system are preserved is still not clear.
One key downstream signal of TRPA1 in migraine
may involve CGRP as previously studies reported that
TRPA1 activation mediates ROS-induced CGRP release
in the rat trigeminal ganglion [10] and in the dura mater
[22]; whilst exogenous CGRP is able to reverse the in-
hibitory action on CSD under TRPA1 deactivation in
vitro [5]. Yet, how these signals interact in regulating
cortical susceptibility to CSD is not fully understood. In
the present study, we investigated the role of TRPA1 in
CSD in vivo and further explored functional relationship
among ROS/TRPA1/CGRP in regulating cortical suscep-
tibility to CSD. We demonstrated that deactivation of
TRPA1 reduces not only cortical susceptibility to CSD in
rats but also attenuated CSD-induced cortical lipid per-
oxidation. Our data also showed that the key role of
TRPA1 in regulating cortical susceptibility to CSD is
functionally related to ROS and CGRP and their actions
are of central mechanism. We propose that ROS triggers
TRPA1 activation and CGRP production, which create
a positive feedback loop in regulating cortical suscep-
tibility to CSD. In which way, ROS could facilitate
CSD propagation for the subsequent development of
migraine.
Experimental procedures
Animal use
A total of 30 male Sprague Dawley rats (253.8 ± 40.9 g)
and 36 male C57BL6 mice (21.2 ± 2.7 g, mean ± SD) were
purchased from Shanghai SLAC Laboratory Animal Cor-
poration Ltd. The sample size of animals was estimated
based on previous studies on CSD susceptibility [5, 23].
Animals were housed in the experimental animal Centre
of Soochow University under the agreement with Xi’an
Jiaotong-Liverpool University (XJTLU) for at least one-
week before use. All animal procedures were approved
by the Ethic Review Panel of Soochow University and
performed in accordance with the relevant national and
provincial guidelines.
Immunohistochemistry
TRPA1 expression in cortical neurons and astrocytes of
rats and mice was detected using immunohistochemistry
(IHC). Rats (n = 3) and mice (n = 3) were anaesthetized
with isoflurane (5% in O2:N2O (1:2)), followed by car-
diac perfusion with phosphate buffered saline (PBS, 09–
8912-100, Medicago), fixation with 4% paraformaldehyde
(PFA) overnight and cryo-protected in 10% to 30% su-
crose solution overnight orderly for dehydration. The
brain was embedded in Tissue-Tek® O.C.T Compound
(Sakura, Finetek, Torrance, CA, USA). Coronal sections
(10 μm) between 1 and 1.5 mm posterior to bregma,
which contains somatosensory and motor cortex regions,
were prepared using a cryostat (CM1950, Leica, China).
Brain slices were washed 3 × 15 min in PBS, and then
incubated with a blocking solution (10% normal goat
serum in PBS with 0.1% Tween 20) for 2 h at room
temperature. Double staining was performed with
anti-TRPA1 antibody (1:200, Alomone Labs, ACC-0037)
and either anti-NeuN antibody (1:1000, MAB377) indi-
cating neurons or anti-glial fibrillary acidic protein
(GFAP) antibody (1:200, CST3670) indicating glial cells.
Briefly, after incubation with the primary antibodies
overnight, cortical sections were brought to room
temperature, rinsed in PBS and exposed to the second-
ary antibodies (Alexa Fluor® 488 Goat Anti-Mouse IgG
(H + L) Antibody, 1:500, Invitrogen, A-11029; Alexa
Fluor® 568 Goat Anti-Rabbit IgG (H + L) antibody, 1:500,
Invitrogen, A-11036) in blocking solution for 1 h at
room temperature. The specimens were subsequently
washed with PBS, and incubated with 0.2% of 4′,6-dia-
midino-2-phenylindole (DAPI, Sigma, D8417) for 5 min.
After washed, specimens were mounted with SlowFade®
Gold Antifade Mountant (Invitrogen, S36936). TRPA1
localization in the cortical neurons and astrocytes was
identified using a fluorescence microscope (Nikon,
ECLIPSE Ni-U or confocal microscope, LSM880, Zeiss).
Immuno-negative control was performed by staining of
anti-IgG antibody in the rat and mice cortices.
In vivo surgery for antibody perfusion and CSD induction
in rats
The in vivo surgery for antibody perfusion into the intra-
cerebral ventricle (i.c.v) and CSD induction in rats was
under anesthesia using isoflurane as described previously
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[23, 24]. Total 29 rats were used. Three burr holes were
drilled in the parietal bone of each rat. One burr hole on
the left side was drilled using a dental drill (D-3000,
Otto Muss). This hole was used for implanting a stain-
less steel cannula (0.38 mm i.d, RWD Life Science) into
the i.c.v. (3.5 mm deep from the cortical surface) for the
antibody perfusion at 1 μl/minute, followed by rat recov-
ery. The other two burr holes were drilled 4 days later
on the right side for CSD induction with dura intact (1
mm, i.d, coordinates: 5 mm posterior and 2mm lateral
to bregma) and CSD recording (0.8 mm, i.d, coordinates:
3 mm anterior and 2mm lateral to bregma). A reference
electrode was positioned under the scalp. The depth of
anesthesia was monitored and adjusted according to the
electroencephalogram (EEG) signal, breathing and body
reflex.
On day 4, multiple CSD waves were induced by con-
tinuous perfusion of 2M KCl for 30 min after 1-h tissue
recovery post the surgery. EEG and direct current (DC)
signals were first amplified with a high-impedance input,
AC/DC pre-amplifier (NL834, Digitimer Ltd., UK). The
alternating current component in the 1–30 Hz window
provided the EEG (overall × 5000 amplification) and the
0–30 Hz window provided the extracellular DC potential
(overall × 250 amplification) at sampling rate of 10 HZ.
The recorded EEG variables were monitored by a digital
oscilloscope (DS1000B, RIGOL, China). All the signals
were continuously recorded and digitized by Labview
11.0 (National Instruments). After CSD recording in
vivo, rats were sacrificed immediately and cerebral corti-
ces were dissected, snap frozen for subsequent lipid per-
oxidation analysis.
In vivo experimental design
Our previous data show that deactivation of TRPA1
channel either abolishes or suppresses CSD in vitro [5].
In this study, we investigated whether anti-TRPA1 anti-
body perfused into the i.c.v. could reduce cortical sus-
ceptibility to CSD in rats. Three groups were designed:
(i) pretreatment of the anti-TRPA1 antibody with a total
0.8 μg (Alomone Labs, n = 10) 4 days before CSD induc-
tion. (ii, iii) Unconjugated rabbit IgG (H + L) (Sangon,
D110502, n = 8) with a total 0.8 μg being applied for
both the CSD group and the sham group as controls
(n = 7 in each group).
Lipid peroxidation analysis
We examined whether CSD could increase lipd peroxi-
dation in the rat cerebral cortex; and whether this in-
crease induced by CSD could be prevented after
pretreatment of the anti-TRPA1 antibody. To address
these, Ipsilateral cerebral cortices of rats in both the
anti-IgG and anti-TRPA1 antibodies groups were ho-
mogenized in the cold lysis buffer (Beyotime, P0013)
with 1X protease inhibitor (Roche) on ice, centrifuged
for 10 min at 13000 xg at 4 °C. Total protein levels in
the supernatants were determined using the Bicinchoninic
Acid Kit (Beyotime, P0010). Malondialdehyde (MDA)
levels of these samples indicating the degree of lipid per-
oxidation were measured at 532 nm using the MDA kit
(Beyotime, S0131).
In vitro CSD induction and imaging of mouse brain slices
Given that deactivation of TRPA1-reduced cortical sus-
ceptibility to CSD involves CGRP [5] and CGRP is a
downstream product of ROS [10], we investigated
whether ROS could facilitate CSD induction and how
TRPA1 would interplay with ROS and CGRP in modu-
lating cortical susceptibility to CSD. Preparation of
mouse brain slices and intrinsic optical imaging was as
described in details previously [5]. Briefly, coronal sec-
tions (400 μm) were prepared and perfused with Kreb’s
medium at a rate of 3 ml/minute. CSD was induced in
the somatosensory region of the brain slice by ejection
of KCl. For each KCl application, changes in the
reflected intrinsic optical signal (IOS) in the cortical slice
were recorded for 15 min as reported earlier [5].
In vitro experimental design
Two series of experiments were designed in the mouse
slice. In order to minimize the animal use, two ways
were considered: (i) at least 2 brain slices per mouse
were used on the same day and they were assigned to
different experimental groups; (ii) Where applicable,
relevant data using the same protocol in Series 1 and 2
below as in our recent publication [5] were adopted for
comparison (also see Figs. 5 and 6 legends).
Series 1: We first examined whether exogenous ROS
could facilitate CSD induction in the mouse brain slice
and whether this amplification was counteracted by ROS
inhibition. Submaximal CSD was induced by KCl at 50
mM as described previously [5] in order to uncover a
possible ROS-induced amplification in this phenomenon;
The following four groups were designed: (i) Kreb’s (n = 6)
as control; (ii, iii) 50 μM of the ROS activator, H2O2 (Sino-
pharm Chemical Reagent Ltd., 10,011,218) in the absence
or presence of 3mM of tempol (Aladin, K1520232, n = 7
in each group), a ROS inhibitor that suppresses CSD in
hippocampus slices [11]; (iv) 3mM of tempol alone (n = 7).
We then investigated whether there was a functional
link between ROS and TRPA1 channel activation in
regulating submaximal CSD, and whether this inter-
action would be bidirectional. To test this, another two
groups were designed: (v) 3 mM of tempol in the pres-
ence of 15 μM of the TRPA1 activator, umbellulone
(UMB, Sigma-Aldrich, 083m4714V, n = 6); (vi) whether
facilitation of submaximal CSD by 50 μM of H2O2 could
be reversed by TRPA1 deactivation was also examined
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by co-application with the TRPA1 antagonist, 1 μM of
A967079 (Tocris, Bristol, UK, 4716, n = 6).
In this series, two submaximal CSD episodes were elic-
ited in each experiment with a 45-mintue interval for
brain slice recovery. The drug or vehicle was perfused
45min prior to the 2nd submaximal CSD induction for
1 h, except that H2O2 was pre-incubated with the slice
for 30 min. In order to minimize the animal use, data in
Kreb’s control group were adopted and transformed
from that in Fig. 4 in our previous paper [5].
Series 2: We then investigated whether TRPA1 activa-
tion or exogenous ROS could reverse the reduced cor-
tical susceptibility to CSD by blockade of CGRP. The
following four groups were designed: (x, xi, xii)
anti-CGRP antibody (CST, 14959S, n = 6) at 0.4 μM in
the absence or presence of either 50 μM of the TRPA1
activator, allyl isothiocyanate (AITC, Sigma-Aldrich,
36,682, n = 6) or 50 μM of H2O2 (n = 6); (xiii) the
anti-IgG antibody (Sangon, D110502, n = 6) at 0.025 μM
was as the control.
In this series, two CSD episodes were induced by 260
mM KCl in each experiment with a 2-h interval. The
antibody was pre-incubated with the brain slice for 1 h
starting as soon as the 1st CSD recording was completed
for sufficient antibody-antigen binding. AITC or H2O2
was perfused for 45 min prior to the 2nd CSD induction
for 1 h. In order to minimize the animal use, data in
anti-IgG antibody control group and the anti-CGRP
antibody were adopted and transformed from that in
Fig. 5 in our recent paper [5].
Intrinsic optical image analysis
The image analysis was carried out as described previ-
ously [5]. For all the image sequences, the same area of
interest (AOI) parallel to each CSD wave was selected
and delineated manually in layers 4–6 of the somatosen-
sory cortex that were distant from the site of KCl appli-
cation. For each picture within the sequence, gray levels
of the pixel constituting the AOI were corrected by sub-
tracting the respective dark background. The recorded IOS
that was synchronous with sudden cellular depolarization,
characterizes the excitation phase of CSD. The average gray
level within each AOI was plotted against time to provide a
CSD wave.
Data presentation and statistical analysis
For the in vivo data presentation, electrophysiological
data on CSD was quantified using Labview program as
described previously [14]. Three parameters were de-
fined to reflect cortical susceptibility to CSD: (i) CSD
number in each episode. (ii) CSD latency (minute), i.e.,
the time difference between the start of KCl application
and the starting point of the rising phase of the first
CSD wave. (iii) Area under the curve (AUC, mV ×
minute) of each CSD wave was used to reflect CSD mag-
nitude. The magnitude average in each CSD episode was
used for data comparison.
For the image analysis, CSD was quantified as reported
previously [22]. Latency (second) was calculated by the
time interval between the starting point of KCl ejection
and CSD elicitation. AUC was calculated by gray levels ×
time period. In order to eliminate variations of AOI
chosen in each individual experiment in series 2, CSD la-
tency within each different test were given in the second
CSD episode relative to that of the first CSD wave (i.e.
initial control). CSD magnitude within each different test
were also given in the second CSD episode relative to
that of the first CSD wave (i.e. initial control).
For data analysis, the abnormal distribution test using
Shapiro-Wilk was confirmed using Prism software. All
values for the above in vivo and in vitro experiments
were given in median (range). The Mann-Whitney U test
(one-tailed) was used for comparing CSD data of two in-
dependent groups for significance and correlation ana-
lysis (2-tailed) between MDA level (μmol/mg tissue) and
each CSD parameter. Significant differences are shown
as *p < 0.05, ** p < 0.01 and *** p < 0.001.
Results
TRPA1 was expressed in neurons and astrocytes of
cerebral cortices of rats and mice
TRPA1 was previously reported to be expressed in the
cerebral cortices of rats [16]. In the present study,
TRPA1 expression was observed in both neurons and as-
trocytes of rat cerebral cortices (n = 3), to a larger ex-
tent, in cortical neurons (Fig. 1, upper panel). Similarly,
expression of TRPA1 was also observed in neurons and
astrocytes of the mouse cerebral cortex (Fig. 2, upper
panel, n = 3).
TRPA1 channel deactivation suppressed CSD in rats
Our previous study shows that TRPA1 deactivation in-
hibits CSD in the mouse brain slice [5]. Here we further
investigated whether the TRPA1 channel antibody, per-
fused into the contralateral i.c.v could produce inhibitory
effects on CSD in rats. In the anti-IgG antibody control
group, topical application of 2M KCl for 30 min typic-
ally elicited 6 [3] (in the form of median (range)) CSD
waves that were identified by transient negative shifts of
DC potential (Fig. 3b and c). The CSD latency was 2.4
(1.2) minutes (n = 8, Fig. 3d), and the CSD magnitude
was 6.5 (9.5) mV ×minute (n = 8, Fig. 3e) respectively.
In the anti-TRPA1 antibody group, 0.8 μg of the anti-
body perfused into the contralateral i.c.v. 4 days before
CSD induction significantly reduced CSD number to 4.5
[3] (n = 10, p = 0.0128, Fig. 3c) when compared to the
anti-IgG antibody group. Corresponding to this, CSD la-
tency was prolonged to 2.9 (3.3) minutes (n = 10), which
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was significant when compared to the anti-IgG antibody
control group (p = 0.0416, Fig. 3d). Conversely, CSD
magnitude was reduced to 4.1 (6.2) mV ×minute (n =
10, p = 0.0482, Fig. 3e).
Reduction of cortical susceptibility to CSD by anti-TRPA1
antibody correlated with a lower MDA level
In the anti-IgG antibody sham group, the MDA level in
the ipsilateral cerebral cortex was 0.64 (0.29) μmol/mg
(n = 7, Fig. 4a). Significant increase in MDA level was
observed immediately after CSD induction and the
MDA level reached to 1.07 (0.7) μmol/mg in the ipsilat-
eral cerebral cortices of rats (n = 8, p = 0.0006, Fig. 4a),
suggesting that CSD induces lipid peroxidation. As ex-
pected, 0.8 μg anti-TRPA1 antibody perfused into
contralateral i.c.v. partially prevented the elevation of
MDA level induced by CSD (n = 10). This reduction was
significant from that of the CSD group (p = 0.0273,
Fig. 4a), suggesting that the lipid peroxidation induced by
CSD could be reduced by TRPA1 deactivation.
Correlation analysis of CSD characteristics with levels
of rat ipsilateral cerebral cortical MDA in the anti-IgG
and anti-TRPA1 antibodies groups showed that after
perfusion of the anti-TRPA1 antibody into the i.c.v prior
to CSD induction, the lower level of MDA showed a
positive correlation with the reduced CSD magnitude
(p = 0.0293, r = 0.5135, Fig. 4d), whilst no correlation
with the reduced CSD number (Fig. 4b) and the pro-
longed CSD latency (Fig. 4c) was observed.
ROS facilitated submaximal CSD induction in the mouse
brain slice
We investigated whether ROS could facilitate submaxi-
mal CSD induced by 50mM KCl in the mouse cortical
Fig. 1 Representative images showing immunohistochemistry detection of TRPA1 expression in neurons and astrocytes of rat cerebral cortex.
Double immune-labelling showed TRPA1 expressed in cerebral cortical neurons (upper panel, white arrows) and astrocytes (lower panel, white
arrows). DAPI staining indicates nucleus is shown in blue; TRPA1 in red, NeuN indicates neurons or GFAP indicates glial cells shown in green
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brain slice. In the Kreb’s control group (n = 6), CSD la-
tency was 18.3 [15] seconds in the 2nd CSD episode and
CSD magnitude was 61.5% (55.48%) relative to that in
the 1st CSD episode (Fig. 5b, c). The ROS inhibitor, tem-
pol, at 3 mM (n = 7) significantly prolonged the latency
of submaximal CSD in the 2nd episode with a 2.0-fold
increase relative to that of the Kreb’s group (p = 0.0239,
Fig. 5b); whilst CSD magnitude was reduced to 26.7%
relative to its baseline (p = 0.0111, Fig. 5c). Conversely,
pre-incubation of the ROS activator, H2O2, at 50 μM
(n = 7) shortened the submaximal CSD latency compared
to that of the Kreb’s group (p = 0.0012, Fig. 5b). Corre-
sponding to this, the shortening of submaximal CSD la-
tency by H2O2 was reversed by its co-application with
tempol and significant difference was observed when
compared with tempol alone group (n = 7, p = 0.0041) and
the H2O2 alone group (p = 0.0152, Fig. 5b) respectively.
These data suggest a key role of ROS in facilitating CSD
induction. It was noted that there was no significant dif-
ference in the magnitude of submaximal CSD between
co-application of H2O2 and tempol when compared with
tempol and H2O2 group alone respectively (Fig. 5c).
Fig. 2 Representative images showing immunohistochemistry detection of TRPA1 expression in neurons and astrocytes of mouse cerebral cortex.
Double immune-labelling showed TRPA1 expressed in cerebral cortical neurons (upper panel, white arrows) and astrocytes (lower panel, white
arrows). DAPI staining indicates nucleus is shown in blue; TRPA1 in red, NeuN indicates neurons or GFAP indicates glial cells shown in green
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Bidirectional interplay between TRPA1 and ROS in
regulating CSD
Our previous study shows that activation of TRPA1 by
UMB is capable of facilitating submaximal CSD induc-
tion [5]. Here, we examined the functional interplay be-
tween ROS and TRPA1 in regulating submaximal CSD
induction in the mouse brain slice. We observed that
both the prolonged latency of submaximal CSD and the
reduced magnitude by the antioxidant, tempol, application
at 3 mM was markedly reversed in the presence of the
TRPA1 activator, UMB at 15 μM (n = 6, Fig. 5). There was
significant difference in both CSD latency (p = 0.0006,
Fig. 5b) and magnitude (p = 0.0051, Fig. 5c) when com-
pared with the tempol alone group, suggesting TRPA1 ac-
tivation modulates ROS-mediated CSD. Consistently, the
shortening of the submaximal CSD latency by H2O2 at
50 μM was also reversed by the TRPA1 inhibitor, A967079
at 1 μM (n = 6, p = 0.0163, Fig. 5b). Taken together, these
data suggest a bidirectional link between TRPA1 activa-
tion and ROS in regulating cortical susceptibility to CSD.
It was noted that no significant difference in CSD magni-
tude was observed between H2O2 at 50 μM in the absence
and presence of A967079 at 1 μM (n = 6, Fig. 5c).
Both ROS and TRPA1 activation reversed the reduced
cortical susceptibility to CSD by the anti-CGRP antibody
We further examined whether ROS and TRPA1 activation
would produce similar effects on preventing the reduced
cortical susceptibility to CSD by inhibition of CGRP, a
known target for migraine prevention. As reported previ-
ously [5], the anti-CGRP antibody incubated at 0.4 μM
markedly prolonged CSD latency (n = 6, p = 0.0022, Fig. 6b)
when compared with the anti-IgG antibody group (n = 6).
H2O2 at 50 μM markedly shortened the prolonged CSD la-
tency, which was significant when compared to the
anti-CGRP antibody alone group (n = 6, p = 0.0076, Fig. 6b).
The CSD latency did not reverse to basal level as there was
a significant difference (n = 6, p = 0.0325, Fig. 6b). Similar as
the ROS activator, the TRPA1 activator, AITC at 50 μM, also
significantly reversed the prolonged CSD latency by the
anti-CGRP antibody (n = 6, p = 0.0022, Fig. 6b). The
anti-CGRP antibody did not alter CSD magnitude and nei-
ther H2O2 nor AITC altered CSD magnitude (Fig. 6c).
Discussion
In this study, we demonstrate that TRPA1 deactivation
reduces the likelihood for CSD induction in rats, which
Fig. 3 Effects of the anti-TRPA1 antibody, perfused into the contralateral ventricle, on cortical susceptibility to CSD in rats. a CSD was induced by
topical application of 2 M KCl for 30 min onto cerebral cortex with dura intact via the posterior burr hole on the right parietal bone. The ipsilateral
anterior hole was used for CSD recording. The anti-TRPA1 antibody (i, n = 10) or anti-IgG antibody (ii, n = 8) was perfused through a cannula
implanted in the contralateral ventricle (i.c.v) at 4 days prior to CSD induction. In the sham group (iii), the anti-IgG antibody was i.c.v perfused in
the absence of KCl application as the control (n = 7). The whole ipsilateral cerebral cortical tissue was subsequently used for detecting MDA level
immediately after the in vivo experiment. b A representative trace showing CSD propagation wave after i.c.v perfusion of the anti-IgG antibody.
CSD number, latency (minute) and magnitude (area under the curve of each CSD wave, mV ×minute) were used for quantifying the excitation
phase of CSD. The effects of the anti-TRPA1 antibody at 0.8 μg on CSD number are shown in panel (c), latency in panel (d) and magnitude in
panel (e). All the values shown are median (range). *p < 0.05, Mann-Whitney U test with one-tailed calculation was used for comparison of the
anti-IgG antibody and the anti-TRPA1 antibody group
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coincides with the reduction of ipsilateral cortical lipid
peroxidation promoted by CSD. We also show that the
ROS-facilitated submaximal CSD induction can be re-
versed by deactivation of TRPA1 in the mouse brain
slice; whereas, the reduced cortical susceptibility to CSD
by ROS inhibition in return is reversed by TRPA1 activa-
tion. Furthermore, both ROS and TRPA1 activation are
capable of reversing the prolonged CSD latency under
CGRP inhibition in the mouse brain slice. Our data re-
veal that ROS/TRPA1/CGRP signaling contributes to
CSD induction. We propose that there is a positive feed-
back loop among these signals by which TRPA1 exerts
in stress-associated migraine.
A key finding of the present study is that TRPA1 de-
activation reduces the likelihood for CSD induction in
rats since pre-treatment of the anti-TRPA1 antibody into
the contralateral i.c.v prolonged CSD latency and re-
duced CSD number and magnitude (Fig. 3). These data
are compatible with our previous in vitro study that de-
activation of TRPA1 by both the anti-TRPA1 antibody
and TRPA1 antagonists reduces cortical susceptibility to
CSD [11], whilst TRPA1 activation facilitates the propa-
gation of submaximal CSD in the mouse brain slice [5].
Our study suggest that TRPA1 plays an important role
in migraine pathogenesis through central mechanism.
Given that TRPA1-deficient mice lack allodynia [21] and
TRPA1 channel activation facilitates the development of
neuropathic pain [25], Collectively, anti-TRPA1 therapies
are likely to form a preventive strategy for migraine
prophylaxis.
It is possible that the action of TRPA1 on CSD in rats
involves both neurons and glial cells for the following
reasons. First, the inhibitory role in CSD under TRPA1
deactivation should derivate from the central but not the
peripheral as the anti-TRPA1 antibody perfused into
i.c.v, can diffuse to the cortical regions. Second,
TRPA1-mediated spontaneous Ca2+ influx increase mod-
ulates the spontaneous release of peptide hormones
from rat primary astrocytes [26]. Third, the role of
TRPA1 on CSD is seen in the mouse brain slice where
TPRA1 located in the cerebral cortex rather than indir-
ectly through peripheral TRPA1 [5]. Further, the fact
that TRPA1 is expressed in neurons, and to a lesser ex-
tent, glial cells in cerebral cortices of rats (Fig. 1) and
mice (Fig. 2) support their neuronal and/or glial func-
tions during CSD. Nevertheless, we cannot rule out a
vascular role of TRPA1 in CSD and this requires future
investigation.
Fig. 4 Effects of the anti-TRPA1 antibody on MDA level (μmol/mg protein) induced by CSD in the ipsilateral cerebral cortex of rat and correlation
analysis of each CSD characteristic with levels of cortical ipsilateral MDA between the anti-TRPA1 antibody or anti-IgG antibody groups. a CSD
promoted ipsilateral cortical MDA level, which was inhibited by the pretreatment of anti-TRPA1 antibody perfused into the contralateral i.c.v in
rats. Mann-Whitney U test, one-tailed, for significance between each group (*p < 0.05, ***p < 0.001). The reduced CSD magnitude (d), but not
CSD number (b) and latency (c) positively correlated with a lower MDA level after the anti-TRPA1 antibody perfusion. Red dotted lines indicated
positive correlation between CSD magnitude and MDA level
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CSD induces ROS production in the trigeminal nocicep-
tive system [10]. Here, we show that CSD is capable of pro-
moting cerebral cortical lipid peroxidation in rats (Fig. 4a).
The importance of ROS in CSD is supported by that ex-
ogenous ROS by H2O2 facilitates submaximal CSD induc-
tion in the mouse brain slice and these effects can be
reversed by the antioxidant (Fig. 5). These data are consist-
ent with that ROS inhibition by the antioxidant reduces the
likelihood for CSD occurrence in vivo [11]. Taken together,
we conclude that ROS play crucial roles in CSD elicitation
and propagation. These data also support that CSD is an
important model of stress-related migraine since oxidative
stress is generated by all common migraine triggers [7].
It is known that TRPA1 is sensitive to oxidative stress.
How does TRPA1 interact with ROS during CSD? Here
we show that ROS is involved in TRPA1 signaling in
modulating CSD as deactivation of TRPA1 channel is
able to reduce cortical susceptibility to CSD, which coin-
cides with a lower level of ROS (Fig. 4d). It should be
noted that no correlation with the reduced CSD number
(Fig. 4b) and the increase in CSD latency (Fig. 4c) was
seen relative to control. The reason to account for the
correlation difference with different CSD parameters are
not known, which requires further investigation. Interest-
ingly, our data show a bidirectional interaction between
ROS and TRPA1 in mediating cortical susceptibility to
Fig. 5 Effects of modulation of ROS and TRPA1 on cortical susceptibility to CSD and their interaction during CSD in the mouse brain slice. Submaximal
CSD was induced by KCl at 50mM. There were six groups: Kreb’s (i, n = 6) as control, 3mM of the ROS inhibitor, tempol (ii, n = 7), 50 μM of ROS activator,
H2O2 (iii, n = 6), 3mM of tempol with 50 μM of H2O2 (vi, n = 8) or with 15 μM of the TRPA1 agonist, UMB (v, n = 7), 50 μM of H2O2 with 1 μM of the TRPA1
antagonist, A967079 (vi, n = 6). In order to minimize the animal use, data in Kreb’s control group were adopted and transformed from that in Fig. 4 in our
previous paper [5]. Representative trace of the 2nd CSD episode in each group were shown in the panel a. The data showed that cortical susceptibility to
CSD is suppressed by tempol, facilitated by H2O2, and there is a bidirectional interaction between ROS and TRPA1 in modulating latency (b)
and magnitude (c) of CSD. CSD latency (second) was given as median (rang). CSD magnitude were plotted as percentage of their initial
levels (1st CSD episode) and indicated as median (range). Mann-Whitney U test (one-tailed) was for significant analysis between two independent
groups. * p < 0.05, ** p < 0.01, ***p < 0.001 indicate significance
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CSD in the mouse brain slice (Fig. 5). On one side, facilita-
tion of submaximal CSD induction by exogenous ROS,
H2O2, can be reversed under TRPA1 antagonism by
A-967079 (Fig. 5), suggesting ROS regulates TRPA1 activity
in mediating CSD. On the other side, TRPA1 activation in
return reverses the prolonged CSD latency and reduced
CSD magnitude by ROS inhibition (Fig. 5). These data are
compatible with reports that degradation of H2O2 prevents
NADPH-induced TRPA1 activation in cerebral endothe-
lium of mice [27]. It is reasonable to propose that ROS is
required for TRPA1 signaling in migraine progression.
Another finding of this study is that TRPA1/CGRP sig-
naling plays a critical role in regulating cortical suscepti-
bility to CSD. First, the reduced cortical susceptibility is
observed under both TRPA1 deactivation (Fig. 3) and
CGRP antagonism (Fig. 6) as that was reported previ-
ously [5]. Second, the involvement of CGRP in cortical
TRPA1 signaling in CSD was supported by that exogen-
ous CGRP abrogates the suppressive effect of TRPA1 an-
tagonism on CSD in the mouse brain slice [5]; whereas
TRPA1 activation in return reverses the prolonged CSD
latency under CGRP antagonism (Fig. 6b). These data
Fig. 6 Both ROS and the TRPA1 activation reversed the inhibitory effects of the anti-CGRP antibody on CSD in the mouse brain slice. CSD was
induced by 260 mM KCl. There were four groups: anti-IgG antibody at 0.025 μM (i, n = 6) as the control, anti-CGRP antibody at 0.4 μM in
the absence (ii, n = 6) or presence of 50 μM of the TRPA1 agonist, AITC (iii, n = 6) or the ROS activator, H2O2 (vi, n = 6). In order to minimize
the animal use, data in anti-IgG antibody control group and the anti-CGRP antibody were adopted and transformed from that in Fig. 5 in our recent
paper [5]. Representative trace of the 2nd CSD episode in each group are shown in the panel a. The data showed that both ROS and the TRPA1
activation reversed the prolonged CSD latency (b), but not magnitude (c) under the perfusion of the anti-CGRP antibody. Data were plotted
as percentage of their initial levels (1st CSD episode) and indicated as median (range). Mann-Whitney U test, one-tailed, was used for significant
analysis between two independent groups. *p < 0.05, **p < 0.01. Abbreviation: Ab indicates antibody
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suggest that TRPA1 and CGRP have bidirectional inter-
action in regulating cortical susceptibility to CSD. As of
TRPA1, the role of CGRP during CSD observed in this
study is also from central since the mouse brain slice
was used. Yet, how TRPA1 and CGRP mutually interact
in regulating cortical susceptibility to CSD requires fur-
ther study.
We found, similar as TRPA1 activation, the ROS acti-
vator also reverses the prolonged CSD latency by the
anti-CGRP antibody (Fig. 6b). It is likely that ROS may
facilitate CGRP production, which enables ROS being
capable of reversing the reduced cortical susceptibility to
CSD after CGRP inhibition (Fig. 6). This is supported by
that ROS facilitates CGRP production in trigeminal
nociceptive system [10] and that multiple CSD induces
both ROS production in rat cortices (Fig. 4a) and CGRP
production in both brain slices and cerebral cortices of
rats [6, 28]. Given that there is an interaction among
ROS, TRPA1 and CGRP in mediating CSD as discussed
above and inhibition of TRPA1 blocks ROS-induced
CGRP release [29], we propose that ROS triggers both
TRPA1 activation and CGRP production, which create a
positive feedback loop in regulating cortical susceptibil-
ity to CSD (Fig. 7). In which way, ROS could facilitate
CSD propagation for the subsequent development of
migraine. This proposal is in line with reports that
TRPA1 activation by environmental irritants stimu-
lates CGRP release in rat trigeminal ganglia neurons
[29] and inhibition of TRPA1 activation blocks ROS-
induced CGRP release [10]. However, whether deacti-
vation of TRPA1 channel prior to CSD induction
would subsequently regulate CGRP production re-
mains further investigation.
Conclusion
ROS/TRPA1/CGRP signaling plays a critical role in
regulating cortical susceptibility to CSD, which is of cen-
tral mechanism. We propose that there is a positive
feedback loop among these signals by which TRPA1 ex-
erts in stress-associated migraine. Anti-CGRP therapies
have brought great hopes for effective prevention of
episodic and chronic migraine, yet there are still
non-responders to these therapies [4]. Our data suggest
that reduction of ROS production and blockade of
TRPA1 may provide alternative therapeutic benefits to
CGRP in preventing migraine. These signals may also
have clinical implications to traumatic brain injury as
CSD also occurs following acute brain injuries and
strokes [30, 31].
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